Eyenovia Phase 3 CHAPERONE myopia trial fails; cuts 50% staff, explores strategic options

HYPERION DEFI, INC.

Independent DRC found CHAPERONE not meeting primary endpoint of <0.5 diopter progression over 3 years; study terminated.
252 evaluable patients; no significant difference between active arms (0.01% and 0.1% atropine) and placebo.
Workforce reduction of ~50% with $0.2M severance; remaining staff focused on Optejet Gen-2, dry eye collaborations, clobetasol.
Company evaluating strategic options: business combination, reverse merger, or asset sales.
Safety profile acceptable; mild and infrequent adverse events across all doses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.